Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Mind Medicine Mindmed Inc
(NQ:
MNMD
)
9.120
-0.490 (-5.10%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 9, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Mind Medicine Mindmed Inc
< Previous
1
2
3
4
Next >
MindMed to Participate at May Investor Conferences
Today 16:01 EDT
From
MindMed
Via
Business Wire
New Studies Presented at the International Society for Health Economics and Outcomes Research Meeting (ISPOR 24) Show Growing Burden and Impact of Generalized Anxiety Disorder (GAD) in the US
Today 8:00 EDT
From
Mind Medicine (MindMed) Inc.
Via
Business Wire
MindMed Reports First Quarter 2024 Financial Results and Business Updates
May 08, 2024
From
MindMed
Via
Business Wire
MindMed Presents Phase 2b Study of MM120 for Generalized Anxiety Disorder (GAD) at American Psychiatric Association (APA) Annual Meeting in New York
May 04, 2024
From
MindMed
Via
Business Wire
MindMed to Host Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Business Update
May 02, 2024
From
MindMed
Via
Business Wire
MindMed to Present at Upcoming May Medical Conferences
April 25, 2024
From
MindMed
Via
Business Wire
MindMed to Present at Upcoming April Medical Conferences
April 02, 2024
From
Mind Medicine
Via
Business Wire
MindMed Announces Voluntary Delisting from Cboe Canada
April 01, 2024
From
MindMed
Via
Business Wire
The Next Great Biotech Boom Has Arrived
March 19, 2024
EQNX::TICKER_START (NYSE:JNJ),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:ATAI),(NYSE:ABBV) EQNX::TICKER_END
Via
FinancialNewsMedia
MindMed to Participate in the Leerink Partners 2024 Global Biopharma Conference
March 11, 2024
From
MindMed
Via
Business Wire
Mind Medicine (MindMed) Inc. Announces Pricing of Underwritten Offering of Common Shares and Concurrent Private Placement
March 07, 2024
From
Mind Medicine (MindMed) Inc.
Via
Business Wire
MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder
March 07, 2024
From
Mind Medicine (MindMed) Inc.
Via
Business Wire
MindMed to Host Conference Call and Webcast to Discuss Data Update for MM120
March 01, 2024
From
MindMed
Via
Business Wire
MindMed Reports 2023 Financial Results and Business Updates
February 28, 2024
From
MindMed
Via
Business Wire
MindMed to Host Conference Call and Webcast to Discuss 2023 Financial Results and Provide Business Update
February 22, 2024
From
MindMed
Via
Business Wire
MindMed to Participate in the 34th Annual Oppenheimer Healthcare Life Sciences Conference
February 07, 2024
From
MindMed
Via
Business Wire
How Psychedelic-Based Therapeutics Are Advancing in Treating Generalized Anxiety Disorder (GAD) Condition
January 24, 2024
EQNX::TICKER_START (NYSE:CYBN),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:SEEL),(NASDAQ:ATAI) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
Product Safety
MindMed Announces Business Update and Anticipated Milestones for 2024
January 08, 2024
From
Mind Medicine (MindMed) Inc.
Via
Business Wire
MindMed Announces Positive Topline Results from Phase 2b Trial of MM-120 in Generalized Anxiety Disorder
December 14, 2023
From
Mind Medicine
Via
Business Wire
MindMed Reports Third Quarter 2023 Financial Results and Business Highlights
November 02, 2023
From
Mind Medicine
Via
Business Wire
MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2023 Financial Results and Provide Business Update
October 26, 2023
From
Mind Medicine (MindMed) Inc.
Via
Business Wire
MindMed Completes Enrollment of Phase 2a Trial of MM-120 in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD)
October 24, 2023
From
Mind Medicine Inc.
Via
Business Wire
MindMed to Present Data on the Preclinical Activity of MM-402 at the 36th Annual European College of Neuropsychopharmacology (ECNP) Congress
October 03, 2023
From
Mind Medicine Inc
Via
Business Wire
Demand for Abuse Deterrent Formulation Technology Skyrocketing as Opiate Abuse is on the Rise
September 20, 2023
EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:CMND),(NASDAQ:MNMD),(NYSE:CYBN),(NYSE:LLY) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Death
Intellectual Property
Exposures
Death
Intellectual Property
The Breakthrough Therapy Aiming To Solve The World’s Mental Health Crisis
September 19, 2023
EQNX::TICKER_START (NYSE:JNJ),(NYSE:ABBV),(NASDAQ:ATAI),(NASDAQ:CMPS),(NASDAQ:MNMD) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Economy
Exposures
Economy
Product Safety
MindMed to Participate in the TD Cowen 3rd Annual Novel Mechanisms in Neuropsychiatry Summit
September 14, 2023
From
MindMed
Via
Business Wire
MindMed Completes Enrollment of Phase 2b Trial of MM-120 in Generalized Anxiety Disorder (GAD)
September 12, 2023
From
Mind Medicine (MindMed) Inc.
Via
Business Wire
The Strategic Brilliance of Acquiring High Times IP, Including Existing Licensing Agreements and Royalty Streams in All-Stock Transaction
September 07, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
MindMed to Participate at September Investor Conferences
August 28, 2023
From
Mind Medicine (MindMed) Inc.
Via
Business Wire
MindMed Secures $50.0 Million Credit Facility with K2 HealthVentures
August 14, 2023
From
Mind Medicine (MindMed) Inc.
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.